These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18453560)

  • 1. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells.
    Silk JD; Salio M; Reddy BG; Shepherd D; Gileadi U; Brown J; Masri SH; Polzella P; Ritter G; Besra GS; Jones EY; Schmidt RR; Cerundolo V
    J Immunol; 2008 May; 180(10):6452-6. PubMed ID: 18453560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
    Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T
    J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-glycosidic compounds can stimulate both human and mouse iNKT cells.
    Jukes JP; Gileadi U; Ghadbane H; Yu TF; Shepherd D; Cox LR; Besra GS; Cerundolo V
    Eur J Immunol; 2016 May; 46(5):1224-34. PubMed ID: 26873393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient activation of Valpha14 invariant NKT cells by foreign lipid antigen is associated with concurrent dendritic cell-specific self recognition.
    Cheng L; Ueno A; Cho S; Im JS; Golby S; Hou S; Porcelli SA; Yang Y
    J Immunol; 2007 Mar; 178(5):2755-62. PubMed ID: 17312118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d.
    Yu KO; Im JS; Illarionov PA; Ndonye RM; Howell AR; Besra GS; Porcelli SA
    J Immunol Methods; 2007 May; 323(1):11-23. PubMed ID: 17442335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
    Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
    J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses.
    Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; Hooijberg E; Kramer D; Reurs AW; van den Eertwegh AJ; von Blomberg BM; Scheper RJ; Bontkes HJ
    J Immunol; 2008 Aug; 181(4):2446-54. PubMed ID: 18684935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation.
    McCarthy C; Shepherd D; Fleire S; Stronge VS; Koch M; Illarionov PA; Bossi G; Salio M; Denkberg G; Reddington F; Tarlton A; Reddy BG; Schmidt RR; Reiter Y; Griffiths GM; van der Merwe PA; Besra GS; Jones EY; Batista FD; Cerundolo V
    J Exp Med; 2007 May; 204(5):1131-44. PubMed ID: 17485514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor.
    Borg NA; Wun KS; Kjer-Nielsen L; Wilce MC; Pellicci DG; Koh R; Besra GS; Bharadwaj M; Godfrey DI; McCluskey J; Rossjohn J
    Nature; 2007 Jul; 448(7149):44-9. PubMed ID: 17581592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD1c enhances human invariant NKT cell activation by α-GalCer.
    Fox LM; Miksanek J; May NA; Scharf L; Lockridge JL; Veerapen N; Besra GS; Adams EJ; Hudson AW; Gumperz JE
    Cancer Immun; 2013; 13():9. PubMed ID: 23885215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of natural killer T cells in antitumor immunotherapy.
    Hong C; Park SH
    Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of invariant NKT cells by the helminth parasite schistosoma mansoni.
    Mallevaey T; Zanetta JP; Faveeuw C; Fontaine J; Maes E; Platt F; Capron M; de-Moraes ML; Trottein F
    J Immunol; 2006 Feb; 176(4):2476-85. PubMed ID: 16456008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop.
    Matulis G; Sanderson JP; Lissin NM; Asparuhova MB; Bommineni GR; Schümperli D; Schmidt RR; Villiger PM; Jakobsen BK; Gadola SD
    PLoS Biol; 2010 Jun; 8(6):e1000402. PubMed ID: 20585371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected].
    Stanic AK; Shashidharamurthy R; Bezbradica JS; Matsuki N; Yoshimura Y; Miyake S; Choi EY; Schell TD; Van Kaer L; Tevethia SS; Roopenian DC; Yamamura T; Joyce S
    J Immunol; 2003 Nov; 171(9):4539-51. PubMed ID: 14568927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human invariant NKT cells are required for effective in vitro alloresponses.
    Patterson S; Kotsianidis I; Almeida A; Politou M; Rahemtulla A; Matthew B; Schmidt RR; Cerundolo V; Roberts IA; Karadimitris A
    J Immunol; 2005 Oct; 175(8):5087-94. PubMed ID: 16210612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cell-type specific CD1d expression program modulates invariant NKT cell development and function.
    Zimmer MI; Colmone A; Felio K; Xu H; Ma A; Wang CR
    J Immunol; 2006 Feb; 176(3):1421-30. PubMed ID: 16424169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White)F1 mice.
    Forestier C; Molano A; Im JS; Dutronc Y; Diamond B; Davidson A; Illarionov PA; Besra GS; Porcelli SA
    J Immunol; 2005 Jul; 175(2):763-70. PubMed ID: 16002672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells.
    Metelitsa LS; Naidenko OV; Kant A; Wu HW; Loza MJ; Perussia B; Kronenberg M; Seeger RC
    J Immunol; 2001 Sep; 167(6):3114-22. PubMed ID: 11544296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-glycerophospholipids activate murine phospholipid-reactive T cells and inhibit iNKT cell activation by competing with ligands for CD1d loading.
    Halder RC; Tran C; Prasad P; Wang J; Nallapothula D; Ishikawa T; Wang M; Zajonc DM; Singh RR
    Eur J Immunol; 2019 Feb; 49(2):242-254. PubMed ID: 30508304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.